The suppression of NF-κB activity was also reported as major mechanism by which down-regulation of CK2 sensitizes prostate cancer cells to the antitumor effect of TRAIL; however, in this case the crucial p65 phosphorylation site was Ser536 [35]. The gene discussed is NFKB1; the disease is prostate carcinoma.